Adamas Pharmaceuticals Inc (OQ:ADMS)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 1900 Powell St Ste 1000
EMERYVILLE CA 94608-1839
Tel: N/A
Website: https://adamaspharma.com
IR: See website
<
Key People
David L. Mahoney
Lead Independent Chairman of the Board
Neil McFarlane
Chief Executive Officer, Director
Christopher B. Prentiss
Chief Financial Officer, Chief Accounting Officer, Principal Financial Officer and Principal Accounting Officer
Jennifer J Rhodes
Chief Compliance Officer, General Counsel, Corporate Secretary, Chief Business Officer
Rajiv Patni
Chief Medical Officer
Vijay Shreedhar
Chief Commercial Officer
Business Overview
Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. It has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD). It has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures).
Financial Overview
For the nine months ended 30 September 2019, Adamas Pharmaceuticals Inc revenues increased 85% to $38.3M. Net loss decreased 20% to $82.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Interest expense decrease of 26% to $11.4M (expense), Other Research and Development. decrease of 12% to $23.3M (expense).
Employees: 134 as of Sep 30, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $157.49M as of Sep 30, 2019
Annual revenue (TTM): $51.60M as of Sep 30, 2019
EBITDA (TTM): -$96.65M as of Sep 30, 2019
Net annual income (TTM): -$110.99M as of Sep 30, 2019
Free cash flow (TTM): -$85.48M as of Sep 30, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 27,857,726 as of Oct 31, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization